12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Secukinumab: Additional Phase II data

Data from a subgroup of 131 patients with hand and/or foot plaque psoriasis in the double-blind, international Phase II Study CAIN457A2211 trial in 404 patients showed that a significantly greater proportion of patients receiving the early regimen of 150 mg subcutaneous secukinumab achieved an IGA response at week 12 vs. placebo (54.3% vs. 19.2%, p=0.005). IGA responses were defined as an Investigator's Global Assessment (IGA) score of "clear" or "minimal" and an improvement of >=2 points on the IGA 5-point scale from baseline at week 12. There was no significant difference between placebo and the monthly...

Read the full 457 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >